Sosei Group Corporation SOLTF is pleased to announce that its
wholly-owned subsidiary Heptares Therapeutics and
AstraZeneca AZN have entered into a licensing agreement under which
AstraZeneca will acquire exclusive global rights to develop, manufacture
and commercialise the adenosine A2A receptor antagonist,
HTL-1071, a small molecule immuno-oncology candidate, and potential
additional A2A receptor-blocking compounds. AstraZeneca will
focus on exploring HTL-1071 and any additional compounds across a range
of cancers, including in combination with its existing portfolio of
immunotherapies.
Tumour cells have evolved mechanisms to evade the immune system,
including through the production of a natural molecule called adenosine.
By stimulating A2A receptors, adenosine stops T-cells within
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in